THE001, a thermosensitive doxorubicin liposome for soft tissue sarcomas, received FDA orphan drug designation, offering ...

DRP® Platform Expansion Beyond Small Molecules: At AACR 2025, Allarity presented a novel DRP® for daratumumab in multiple myeloma, marking the Company's first DRP developed for a targeted antibody ...

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

The daratumumab DRP ® was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent cellular cytotoxicity ... Allarity’s website later today, ...

Our team of proven drug developers is advancing an antibody-drug conjugate with our ... from currently approved therapies such as PD-1/L1 inhibitors ...

The daratumumab DRP ® was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent ... following 1:00 p.m. ET, in the Scientific Publications ...

The poster will be made available on Allarity’s website later today, following 1:00 p.m. ET ... the expansion of the DRP® platform to antibody-based therapies, and the Company’s ability ...

TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing ...

The daratumumab DRP ® was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent cellular cytotoxicity (ADCC), based on published in vitro data ...